Live Breaking News & Updates on Nuclear Medicine At Kanazawa University Hospital

First Patient Dosed in Japanese Prostate Cancer Imaging Study
May 24, 2021 21:04 ET
| Source:
Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited
North Melbourne, AUSTRALIA
MELBOURNE, Australia and KYOTO, Japan, May 25, 2021 (GLOBE NEWSWIRE) Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a clinical study in Japan using Telix’s investigational prostate cancer imaging product TLX591-CDx (Illuccix
®, Kit for the preparation of
68Ga-PSMA-11 injection). The study is an academic collaboration between Telix and Kanazawa University.
The study will enroll ten patients with advanced prostate cancer and is the first clinical evaluation of gallium-based PSMA imaging in Japan. The objective is to obtain safety data in a representative Japanese patient population, and to demonstrate that the targeting and biodistribution of T ....

United States , Cdx Illuccix , Shintaro Nishimura , Stewart Holmstrom , Christian Behrenbruch , Kanazawa Advanced Medical Center Kadmedic , Telix Pharmaceuticals , Kanazawa University , Australian Securities Exchange , Innovative Clinical Research Center , Australian Therapeutic Goods Administration , European Union , Corporate Communications , Telix Pharmaceuticals Limited , Nuclear Medicine At Kanazawa University Hospital , Kanazawa University Hospital , Pharmaceuticals Limited , Principal Investigator , Professor Mizokami , Professor Murayama , Professor Kinuya , Nuclear Medicine , Kanazawa Advanced Medical Center , Japan President , Molecularly Targeted Radiation , Australian Stock Exchange Tlx Ax ,